1 Min Read
Feb 28 (Reuters) - Concert Pharmaceuticals Inc:
* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.